Department of Dermatology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Department of Biostatistics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Photodermatol Photoimmunol Photomed. 2023 Sep;39(5):520-526. doi: 10.1111/phpp.12895. Epub 2023 Jun 20.
Pityriasis lichenoides (PL) is a papulosquamous disease affecting both children and adults, for which narrowband-UVB (NB-UVB) phototherapy is regarded as a commonly used treatment option. The aim of this study was to investigate the efficacy of NB-UVB phototherapy in the management of PL and to compare response rates in pediatric and adult age groups.
This observational, retrospective study included 20 PL patients (12 pityriasis lichenoides chronica; PLC, 8 pityriasis lichenoides et varioliformis acuta; PLEVA) who failed to respond to other treatment modalities. The data for this study were collected retrospectively from patient follow-up forms in the phototherapy unit.
A complete response (CR) was obtained in all pediatric patients with PL, while 53.8% of adult patients had achieved CR. The mean cumulative dose required to achieve the CR was higher in pediatric patients than adult patients with PL (p < .05). The CR was achieved in 6 (75%) of 8 PLEVA patients, while 8 (66.7%) of 12 PLC patients had reached to CR. The mean number of exposures for patients with PLC to achieve a CR was higher than patients with PLEVA (p < .05). Erythema was the most common adverse effect during phototherapy particularly in 5 (35.7%) of the patients with PL who had achieved CR.
NB-UVB is an effective and well-tolerated treatment option for PL especially in diffuse types. A higher response can be obtained in children with higher cumulative dose. Patients with PLC may require more exposures for CR than patients with PLEVA.
苔藓样糠疹(PL)是一种影响儿童和成人的丘疹鳞屑性疾病,窄谱 UVB(NB-UVB)光疗被认为是一种常用的治疗选择。本研究旨在探讨 NB-UVB 光疗在 PL 治疗中的疗效,并比较儿童和成年年龄组的反应率。
这是一项观察性、回顾性研究,纳入了 20 例对其他治疗方法无反应的 PL 患者(12 例慢性苔藓样糠疹;PLC,8 例急性苔藓样糠疹样疹;PLEVA)。本研究的数据是从光疗病房的患者随访表中回顾性收集的。
所有儿童 PL 患者均获得完全缓解(CR),而 53.8%的成年 PL 患者达到 CR。达到 CR 的儿童患者所需的平均累积剂量高于成年 PL 患者(p<0.05)。6(75%)例 PLEVA 患者和 8(66.7%)例 PLC 患者达到 CR。达到 CR 的 PLC 患者所需的平均照射次数高于 PLEVA 患者(p<0.05)。红斑是光疗期间最常见的不良反应,尤其是在 12 例达到 CR 的 PL 患者中,有 5 例(35.7%)出现了这种不良反应。
NB-UVB 是治疗 PL 的有效且耐受良好的选择,特别是在弥漫性类型中。儿童患者累积剂量较高,反应率更高。与 PLEVA 患者相比,PLC 患者可能需要更多的照射次数才能达到 CR。